Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… Biology Laboratory of the Department of Medicines and Health Technologies (MTS - Univ. Paris-Saclay/INRAE/CEA) . … of our product. We have observed that DTR8 preserves 60% of healthy glomeruli, compared to only 25% with placebo … product. The drug will be expensive, but it will reduce healthcare costs. Current treatments, which include …Published on: